Tondra Mapus, NP
Family · Sandusky, OHNPI 1225414824
Payments from drug & device makers
Across 161 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$594
- Novo Nordisk$539
- Boehringer Ingelheim$419
- AstraZeneca$307
- Abbott$225
- Corcept Therapeutics$211
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,205100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $594 |
| Novo Nordisk | 28 | $539 |
| Boehringer Ingelheim | 11 | $419 |
| AstraZeneca | 5 | $307 |
| Abbott | 11 | $225 |
| Corcept Therapeutics | 5 | $211 |
| Dexcom, Inc. | 11 | $207 |
| Bayer | 5 | $204 |
| Insulet Corporation | 5 | $197 |
| Recordati_rare_diseases_inc. | 9 | $168 |
| Xeris Pharmaceuticals, Inc. | 8 | $152 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Idorsia Pharmaceuticals US Inc | 1 | $113 |
| Medtronic | 2 | $112 |
| Tandem Diabetes Care, Inc. | 6 | $74 |
| BETA Bionics, Inc. | 3 | $67 |
| Edwards Lifesciences | 1 | $63 |
| Cequr Corporation | 3 | $63 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Ultragenyx Pharmaceutical Inc. | 1 | $58 |
| Sage Therapeutics, LLC | 1 | $55 |
| Harmony Biosciences LLC | 1 | $52 |
| Merck | 2 | $32 |
| Bigfoot Biomedical Inc | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $19 |
| Mannkind Corporation | 1 | $18 |
| Vivus LLC | 1 | $18 |
| GSK | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,217 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 342 | $734,556 |
| JardianceEmpagliflozin | 345 | $439,966 |
| TrulicityDulaglutide | 110 | $233,722 |
| Tresiba Flextouch U-100Insulin Degludec | 162 | $129,353 |
| Humalog Kwikpen U-200Insulin Lispro | 42 | $124,732 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 75 | $87,753 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $77,079 |
| FarxigaDapagliflozin Propanediol | 54 | $65,516 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $53,021 |
| MounjaroTirzepatide | 27 | $45,200 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $42,864 |
| JanuviaSitagliptin Phosphate | 27 | $41,274 |
| FiaspInsulin Aspart (Niacinamide) | 23 | $37,217 |
| Humalog Kwikpen U-100Insulin Lispro | 82 | $29,792 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 138 | $29,447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $539 | $809,224414 claims |
| Boehringer IngelheimJardiance, Tradjenta | $419 | $459,385358 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $594 | $295,054194 claims |
| AstraZenecaFarxiga | $307 | $65,51654 claims |
| MerckJanuvia | $32 | $41,27427 claims |
| Sanofi-aventis U.S. LLCLantus | $60 | $1,88913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Sandusky
- Renee OttSandusky$179K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.